Literature DB >> 26999421

Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.

Nikhil Patkar1, Kiran Ghodke1, Swapnali Joshi1, Shruti Chaudhary1, Russel Mascerhenas1, Sona Dusseja1, Shashikant Mahadik1, Sheetal Gaware1, Prashant Tembhare1, Sumeet Gujral1, Sharayu Kabre2, Pratibha Kadam-Amare2, Hasmukh Jain3, Uma Dangi3, Bhausaheb Bagal3, Navin Khattry3, Manju Sengar3, Brijesh Arora4, Gaurav Narula4, Shripad Banavali4, Hari Menon3, Papagudi Ganesan Subramanian1.   

Abstract

We document the characteristics of BCR-ABL kinase domain mutations (KDM) in the largest study from India comprising of 385 patients and demonstrate that more than half (51.9%) of these patients have detectable abnormalities in the KD both in adult and in pediatric chronic myelogenous leukemia (CML). These comprise singly occurring missense mutations (25.5%), polyclonal/compound point mutations (4.9%), and insertions/deletions (29.6%). Missense mutations were most commonly seen in the imatinib-binding region followed by the P-loop. The commonest mutation in our dataset was T315I. Other common missense mutations were Y253H, M244V, and F317L. A high prevalence of BCR-ABL exon7 deletion (p.R362fs*) was also seen (25.5% of the entire cohort), whereas the 35bpintron-derived insertion/truncation mutation detected in 12 patients. In the pediatric age group, 58.8% of patients harbored missense mutations, polyclonal/compound mutations as well as insertions and deletions. We detected 11 novel mutations (seven missense mutations and four insertions/deletions).

Entities:  

Keywords:  BCR-ABL Kinase domain mutations; CML India; imatinib resistance

Mesh:

Substances:

Year:  2016        PMID: 26999421     DOI: 10.3109/10428194.2016.1157868

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective.

Authors:  K Ghosh
Journal:  J Postgrad Med       Date:  2022 Apr-Jun       Impact factor: 1.566

2.  BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance.

Authors:  Irina Nemchenko; Olga Nesterova; Ilya Mikhailov; Andrey Sudarikov
Journal:  Clin Case Rep       Date:  2018-09-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.